John Najarian has come on CNBC this morning and states that yesterday XTO has seen very active call buying and institutional buying the last couple days.
He stated the last time XTO Energy was this low....crude oil was in the $70's. He said if you want to play crude in a stock...this is the way to do it...usually it moves 2-1 higher or lower.
He also stated that XTO has been active in the Shale Plays which we already know!
XTO is active in the Following Shale Plays
Bakken Shale
Haynesville Shale
Marcellus Shale
Barnett Shale
Friday, July 25, 2008
EPCT - Epicept up 200% Pre Market Drug Approval
Today ECPT - Epicept is up over 200% on approval of Ceplene, one of their drugs.
Ceplene(R) Receives Positive European Opinion for Approval From CHMP
Marketing Authorization Normally Anticipated within 67 Days in the EU
Conference Call to be Held July 28 at 9:00 a.m. Eastern Time
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion regarding the marketing authorization for Ceplene® (histamine dihydrochloride), for the remission maintenance and prevention of relapse in adult patients with Acute Myeloid Leukemia (AML) in first remission. Ceplene is to be administered in conjunction with low-dose interleukin-2 (IL-2). This positive opinion was issued following a request made by EpiCept to have the initial negative opinion of March 2008 re-examined by the CHMP. Ceplene has been designated as an orphan medicinal product, and as such is entitled to 10 years of marketing exclusivity in the EU
Ceplene(R) Receives Positive European Opinion for Approval From CHMP
Marketing Authorization Normally Anticipated within 67 Days in the EU
Conference Call to be Held July 28 at 9:00 a.m. Eastern Time
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion regarding the marketing authorization for Ceplene® (histamine dihydrochloride), for the remission maintenance and prevention of relapse in adult patients with Acute Myeloid Leukemia (AML) in first remission. Ceplene is to be administered in conjunction with low-dose interleukin-2 (IL-2). This positive opinion was issued following a request made by EpiCept to have the initial negative opinion of March 2008 re-examined by the CHMP. Ceplene has been designated as an orphan medicinal product, and as such is entitled to 10 years of marketing exclusivity in the EU
Subscribe to:
Posts (Atom)
